



Why Create a National Cooperative Group?

Jonathan S. Berek MD MMS

Laurie Kraus Lacob Professor

Stanford University School of Medicine

Fellow, Stanford Distinguished Careers Institute

Director, Stanford Women's Cancer Center

Senior Scientific Advisor, Stanford Cancer Institute

Gynecologic Cancer InterGroup

GYNECOLOGIC
CANCER INTERGROUP

An Organization of International Cooperative
Groups for Clinical Trials in Gynecologic Cancers



GCIG Education Symposium, November 2017, Vienna



What are the arguments and reasons for National Cooperative Groups?

What might be the benefits/advantages?

What are the barriers/impediments?



Challenges

Individual sites need to be compliant with the rules of the group

The maintenance of records must be of very high quality and standardized

Data management must be impeccable

Group needs excellent statistical analysis via biostatistician



Why Create a National Cooperative Group?

Standardization of Protocols

Answer key question more quickly

Speed accrual of patients

Standard IRB & informed consent processes



Why Create a National Cooperative Group?

Improve Interaction amongst treatment sites

Diversity of protocols

Increase in innovative ideas

Improve collegiality amongst our colleagues



National Cooperative Group

Groups can then do clinical trials by cooperating with other groups--

the GCIG!